当前位置： SCI文献检索 > BREAST CANCER RESEARCH期刊下所有文献 > Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.

Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.

Abstract：

BACKGROUND:Fragments of collagen type I containing the epitope AHDGGR (CTX) are generated during bone resorption. The aspartyl-glycine (DG) site within CTX is synthesised in the L-aspartyl peptide (alphaL) form, but converts to the age-modified forms L-isoaspartyl peptide (betaL) and D-aspartyl peptide (alphaD) over time. The purpose of the present study was to test the ability of the various CTX forms to identify breast cancer patients with bone metastases and to investigate whether such patients had an altered CTX excretion pattern. METHODS:In this cross-sectional study we compared CTX excretion in healthy premenopausal and postmenopausal women with CTX levels in patients with breast cancer. The breast cancer cohort comprised eight hypercalcemic patients with bone metastases (HC+), 100 normocalcemic patients with bone metastases (NC+) and 15 normocalcemic patients without bone metastases (NC-). RESULTS:In HC+ patients and NC+ patients, the excretion of alphaL CTX was highly increased compared with NC- patients (P < 0.01), with Z scores of 3.4 and 2.0, respectively. The excretion of the age-modified forms (betaL and alphaD CTX) was less increased in HC+ patients and in NC+ patients as compared with NC- patients, with Z scores of 2.2 and 1.0, respectively, for betaL CTX, and of 1.6 and 0.8, respectively, for alphaD CTX. CONCLUSION:Assays for the various isoforms of CTX have different sensitivities to identify patients affected by bone metastases. The alphaL CTX isoform reflecting resorption of young bone appeared to provide the best differentiation of patients affected by breast cancer-induced bone metastases. In conclusion, patients affected by metastatic bone disease present an altered excretion pattern of CTX isoforms.

journal_name

Breast Cancer Res

journal_title

Breast cancer research : BCR

authors

Cloos PA,Christgau S,Lyubimova N,Body JJ,Qvist P,Christiansen C

doi

10.1186/bcr607

keywords:

subject

Has Abstract

pub_date

2003-01-01 00:00:00

pages

R103-9

issue

4

eissn

1465-5411

issn

1465-542X

journal_volume

5

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH文献大全
  • Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status.

    abstract：INTRODUCTION:MBD2, the gene encoding methyl-CpG-binding domain (MBD)2, is a major methylation related gene and functions as a transcriptional repressor that can specifically bind to the methylated regions of other genes. MBD2 may also mediate gene activation because of its potential DNA demethylase activity. The presen...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1283

    authors： Zhu Y,Brown HN,Zhang Y,Holford TR,Zheng T

    更新日期：2005-01-01 00:00:00

  • The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.

    abstract：BACKGROUND:The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of cyclophosphamide-based adjuvant chemotherapy in premenopausal patients with high-risk breast...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-018-1012-0

    authors： Jensen MB,Lænkholm AV,Nielsen TO,Eriksen JO,Wehn P,Hood T,Ram N,Buckingham W,Ferree S,Ejlertsen B

    更新日期：2018-07-27 00:00:00

  • CXCL17-derived CD11b+Gr-1+ myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB.

    abstract：BACKGROUND:Metastasis is the major cause of death from breast cancer. Colonization and adaption of metastatic cells in distant organs is a rate-limiting step of the cancer spreading. The underlying mechanisms responsible for the colonization of breast cancer to lung metastatic niches are not fully understood. METHODS:...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-019-1114-3

    authors： Hsu YL,Yen MC,Chang WA,Tsai PH,Pan YC,Liao SH,Kuo PL

    更新日期：2019-02-12 00:00:00

  • Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.

    abstract：INTRODUCTION:Triple-negative breast cancer does not express estrogen and progesterone receptors, and no overexpression/amplification of the HER2-neu gene occurs. Therefore, this subtype of breast cancer lacks the benefits of specific therapies that target these receptors. Today chemotherapy is the only systematic thera...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2606

    authors： Gründker C,Föst C,Fister S,Nolte N,Günthert AR,Emons G

    更新日期：2010-01-01 00:00:00

  • Circulating DNA as biomarker in breast cancer.

    abstract：:As the release of tumor-associated DNA into blood circulation is a common event in patients with cancer, screening of plasma or serum DNA may provide information on genetic and epigenetic profiles associated with breast cancer development, progression, and response to therapy. Quantitative testing of circulating DNA c...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/s13058-015-0645-5

    authors： Schwarzenbach H,Pantel K

    更新日期：2015-10-09 00:00:00

  • Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1.

    abstract：INTRODUCTION:Oestrogens can mediate some of their cell survival properties through a nongenomic mechanism that involves the mitogen-activated protein kinase (MAPK) pathway. The mechanism of this rapid signalling and its dependence on a membrane bound oestrogen receptor (ER), however, remains controversial. The role of ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1509

    authors： Lim KT,Cosgrave N,Hill AD,Young LS

    更新日期：2006-01-01 00:00:00

  • Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.

    abstract：INTRODUCTION:Breast cancers frequently metastasise to the skeleton where they cause osteolytic bone destruction by stimulating osteoclasts to resorb bone and by preventing osteoblasts from producing new bone. The Runt-related transcription factor 2, Runx2, is an important determinant of bone metastasis in breast cancer...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3048

    authors： Mendoza-Villanueva D,Zeef L,Shore P

    更新日期：2011-10-27 00:00:00

  • Biology of breast cancer in young women.

    abstract：:Breast cancer arising at a young age is relatively uncommon, particularly in the developed world. Several studies have demonstrated that younger patients often experience a more aggressive disease course and have poorer outcome compared to older women. Expression of key biomarkers, including endocrine receptors, HER2 ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/s13058-014-0427-5

    authors： Azim HA Jr,Partridge AH

    更新日期：2014-08-27 00:00:00

  • Nitric oxide deficiency and endothelial-mesenchymal transition of pulmonary endothelium in the progression of 4T1 metastatic breast cancer in mice.

    abstract：BACKGROUND:Mesenchymal transformation of pulmonary endothelial cells contributes to the formation of a metastatic microenvironment, but it is not known whether this precedes or follows early metastasis formation. In the present work, we characterize the development of nitric oxide (NO) deficiency and markers of endothe...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-018-1013-z

    authors： Smeda M,Kieronska A,Adamski MG,Proniewski B,Sternak M,Mohaissen T,Przyborowski K,Derszniak K,Kaczor D,Stojak M,Buczek E,Jasztal A,Wietrzyk J,Chlopicki S

    更新日期：2018-08-03 00:00:00

  • Clinical trial update: National Cancer Institute of Canada.

    abstract：:The Breast Cancer Site Group (BCSG) of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) has conducted a wide variety of clinical trials focussing on large phase III trials of adjuvant chemotherapy, adjuvant hormonal therapy, and optimal delivery of adjuvant radiation therapy. The Group has al...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr979

    authors： Pritchard K,Whelan T

    更新日期：2005-01-01 00:00:00

  • Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study.

    abstract：INTRODUCTION:Menopausal hormone therapy has been reported to increase the risk of certain subtypes of breast cancer and to be associated with a favorable survival. These associations could either be due to an increased mammographic surveillance or to a biological effect. We assessed these associations in a Swedish coho...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,多中心研究

    doi：10.1186/bcr2145

    authors： Rosenberg LU,Granath F,Dickman PW,Einarsdóttir K,Wedrén S,Persson I,Hall P

    更新日期：2008-01-01 00:00:00

  • Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.

    abstract：BACKGROUND:The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with tamoxifen and letrozole in the letrozole-sensitive MCF7 aromatase expressing model (MCF7AC1), as well ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-020-01286-7

    authors： Jayaraman S,Hou X,Kuffel MJ,Suman VJ,Hoskin TL,Reinicke KE,Monroe DG,Kalari KR,Tang X,Zeldenrust MA,Cheng J,Bruinsma ES,Buhrow SA,McGovern RM,Safgren SL,Walden CA,Carter JM,Reid JM,Ingle JN,Ames MM,Hawse JR,Goet

    更新日期：2020-05-19 00:00:00

  • Intra-operative spectroscopic assessment of surgical margins during breast conserving surgery.

    abstract：BACKGROUND:In over 20% of breast conserving operations, postoperative pathological assessment of the excised tissue reveals positive margins, requiring additional surgery. Current techniques for intra-operative assessment of tumor margins are insufficient in accuracy or resolution to reliably detect small tumors. There...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-018-1002-2

    authors： Shipp DW,Rakha EA,Koloydenko AA,Macmillan RD,Ellis IO,Notingher I

    更新日期：2018-07-09 00:00:00

  • Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.

    abstract：INTRODUCTION:Endocrine therapies target oestrogenic stimulation of breast cancer (BC) growth, but resistance remains problematic. Our aims in this study were (1) to identify genes most strongly associated with resistance to endocrine therapy by intersecting global gene transcription data from patients treated presurgic...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-014-0447-1

    authors： Ribas R,Ghazoui Z,Gao Q,Pancholi S,Rani A,Dunbier A,Dowsett M,Martin LA

    更新日期：2014-10-31 00:00:00

  • Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation.

    abstract：:Targeting the function of epidermal growth factor receptor (EGFR) has failed as an effective clinical option for breast cancer. Understanding the drivers of inherent resistance has been a challenge. One possible mechanism is the acquisition of stem-like properties through the process of epithelial-mesenchymal transiti...

    journal_title：Breast cancer research : BCR

    pub_type： 评论,杂志文章

    doi：10.1186/s13058-014-0448-0

    authors： Brown WS,Wendt MK

    更新日期：2014-09-23 00:00:00

  • PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.

    abstract：INTRODUCTION:Protein tyrosine kinase 6 (PTK6) is a non-receptor tyrosine kinase that is highly expressed in Human Epidermal Growth Factor 2(+) (Her2(+)) breast cancers. Overexpression of PTK6 enhances anchorage-independent survival, proliferation, and migration of breast cancer cells. We hypothesized that PTK6 inhibiti...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0594-z

    authors： Park SH,Ito K,Olcott W,Katsyv I,Halstead-Nussloch G,Irie HY

    更新日期：2015-06-19 00:00:00

  • Breast cancer intra-tumor heterogeneity.

    abstract：:In recent years it has become clear that cancer cells within a single tumor can display striking morphological, genetic and behavioral variability. Burgeoning genetic, epigenetic and phenomenological data support the existence of intra-tumor genetic heterogeneity in breast cancers; however, its basis is yet to be full...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr3658

    authors： Martelotto LG,Ng CK,Piscuoglio S,Weigelt B,Reis-Filho JS

    更新日期：2014-05-20 00:00:00

  • Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases.

    abstract：INTRODUCTION:Breast carcinoma is the most common cancer in women, but its incidence is not increased in Lynch syndrome (LS) and studies on DNA mismatch repair deficiency (MMR) in LS-associated breast cancers have arrived at conflicting results. This study aimed to settle the question as to whether breast carcinoma belo...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3205

    authors： Lotsari JE,Gylling A,Abdel-Rahman WM,Nieminen TT,Aittomäki K,Friman M,Pitkänen R,Aarnio M,Järvinen HJ,Mecklin JP,Kuopio T,Peltomäki P

    更新日期：2012-06-12 00:00:00

  • Identification of signaling pathways in early mammary gland development by mouse genetics.

    abstract：:The mammary gland develops as an appendage of the ectoderm. The prenatal stage of mammary development is hormone independent and is regulated by sequential and reciprocal signaling between the epithelium and the mesenchyme. A number of recent studies using human and mouse genetics, in particular targeted gene deletion...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr776

    authors： Robinson GW

    更新日期：2004-01-01 00:00:00

  • Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence.

    abstract：INTRODUCTION:Menopausal hormone therapy (HT) is typically withheld from breast cancer survivors because of concerns about risk for recurrence. Our objectives were to estimate the effects of HT on recurrence in breast cancer survivors and to examine the reliability of these estimates. METHODS:In a systematic review of ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,meta分析

    doi：10.1186/bcr1035

    authors： Col NF,Kim JA,Chlebowski RT

    更新日期：2005-01-01 00:00:00

  • Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.

    abstract：:Recent studies indicate that constitutive signaling through the phosphatidylinositol 3'-kinase (PI3K) pathway is a cause of treatment resistance in breast cancer patients. This implies that patients with tumors that exhibit aberrant PI3K signaling may benefit from targeted pathway inhibitors. The first agents to make ...

    journal_title：Breast cancer research : BCR

    pub_type： 评论,杂志文章

    doi：10.1186/bcr1307

    authors： Crowder RJ,Ellis MJ

    更新日期：2005-01-01 00:00:00

  • Whither high-dose chemotherapy in breast cancer?

    abstract：:Four trials of high-dose chemotherapy with stem cell support in breast cancer in the adjuvant and metastatic settings have shown no long-term disease-free or overall survival gain. This relative failure of a single high-dose therapy we believe opens up the development of a dose-dense approach with block scheduling as ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr262

    authors： Mayer A,Earl H

    更新日期：2001-01-01 00:00:00

  • Inducible transgenics. New lessons on events governing the induction and commitment in mammary tumorigenesis.

    abstract：:Breast cancer arises from multiple genetic events that together contribute to the established, irreversible malignant phenotype. The development of inducible tissue-specific transgenics has allowed a careful dissection of the events required for induction and subsequent maintenance of tumorigenesis. Mammary gland targ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr297

    authors： Hulit J,Di Vizio D,Pestell RG

    更新日期：2001-01-01 00:00:00

  • Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer.

    abstract：:Transforming growth factor-beta (TGF-beta) is a tumor suppressor, the function of which is compromised in many types of human cancer, including breast cancer. The tumor suppressive effects of TGF-beta are caused by potent inhibition of cell proliferation due to cell cycle arrest in the G1 phase. Such antiproliferative...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr42

    authors： Kretzschmar M

    更新日期：2000-01-01 00:00:00

  • Assessing breast cancer cell lines as tumour models by comparison of mRNA expression profiles.

    abstract：INTRODUCTION:Breast cancer researchers use cell lines to model myriad phenomena ranging from DNA repair to cancer stem cell phenotypes. Though appropriate, and even requisite, for many studies, the suitability of cell lines as tumour models has come into question owing to possibilities of tissue culture artefacts and c...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0613-0

    authors： Vincent KM,Findlay SD,Postovit LM

    更新日期：2015-08-20 00:00:00

  • Trastuzumab emtansine: mechanisms of action and drug resistance.

    abstract：:Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tolerated when administered as a single agent to treat advanced breast cancer. Efficacy has now been demonstrated in randomized trials as first line, second line, and later than the second line treatment of advanced breast...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr3621

    authors： Barok M,Joensuu H,Isola J

    更新日期：2014-03-05 00:00:00

  • Familial risks of breast cancer.

    abstract：:A recent analysis by the Collaborative Group on Hormonal Factors in Breast Cancer has provided the most precise quantification to date of the familial risks of breast cancer. The familial relative risks are shown to decrease from more than fivefold in women younger than age 40 years with a first-degree relative aged y...

    journal_title：Breast cancer research : BCR

    pub_type： 社论

    doi：10.1186/bcr448

    authors： Easton DF

    更新日期：2002-01-01 00:00:00

  • Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO).

    abstract：INTRODUCTION:Mutations in BRCA1 and BRCA2 confer a high risk of breast cancer (BC), but the magnitude of this risk seems to vary according to the study and various factors. Although controversial, there are data to support the hypothesis of allelic risk heterogeneity. METHODS:We assessed variation in BC risk according...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3218

    authors： Lecarpentier J,Noguès C,Mouret-Fourme E,Gauthier-Villars M,Lasset C,Fricker JP,Caron O,Stoppa-Lyonnet D,Berthet P,Faivre L,Bonadona V,Buecher B,Coupier I,Gladieff L,Gesta P,Eisinger F,Frénay M,Luporsi E,Lortholary A,

    更新日期：2012-07-03 00:00:00

  • BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.

    abstract：BACKGROUND:In breast cancer, BRCA promoter hypermethylation and BRCA germline mutations are said to occur together rarely, but this property has not yet been translated into a clinical test. Our aim in this study was to investigate the diagnostic value of BRCA1/2 methylation in distinguishing breast carcinomas of BRCA1...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-017-0856-z

    authors： Vos S,Moelans CB,van Diest PJ

    更新日期：2017-05-31 00:00:00

  • Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression.

    abstract：INTRODUCTION:Mammary stem cells are bipotential and suggested to be the origin of breast cancer development, but are elusive and vaguely characterized. Breast tumors can be divided into subgroups, each one requiring specific treatment. To determine a possible association between mammary stem cells and breast cancer, a ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2256

    authors： Williams C,Helguero L,Edvardsson K,Haldosén LA,Gustafsson JA

    更新日期：2009-01-01 00:00:00